Switch theme
Sign up to access all valuation multiples
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company’s drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
2001
5
LTM Revenue $8.9M
LTM EBITDA -$37.9M
$423M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PYC Therapeutics has a last 12-month revenue (LTM) of $8.9M and a last 12-month EBITDA of -$37.9M.
In the most recent fiscal year, PYC Therapeutics achieved revenue of n/a and an EBITDA of -$24.1M.
PYC Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PYC Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $8.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$37.9M | XXX | -$24.1M | XXX | XXX | XXX |
| EBITDA Margin | -427% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$39.3M | XXX | -$38.8M | XXX | XXX | XXX |
| EBIT Margin | -443% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$34.6M | XXX | -$24.2M | XXX | XXX | XXX |
| Net Margin | -390% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, PYC Therapeutics's stock price is AUD 1 (or $1).
PYC Therapeutics has current market cap of AUD 706M (or $453M), and EV of AUD 658M (or $423M).
See PYC Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $423M | $453M | XXX | XXX | XXX | XXX | $-0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, PYC Therapeutics has market cap of $453M and EV of $423M.
PYC Therapeutics's trades at n/a EV/Revenue multiple, and -13.4x EV/EBITDA.
Equity research analysts estimate PYC Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PYC Therapeutics has a P/E ratio of -13.1x.
See valuation multiples for PYC Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $453M | XXX | $453M | XXX | XXX | XXX |
| EV (current) | $423M | XXX | $423M | XXX | XXX | XXX |
| EV/Revenue | 47.6x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -11.1x | XXX | -13.4x | XXX | XXX | XXX |
| EV/EBIT | -10.8x | XXX | -10.6x | XXX | XXX | XXX |
| EV/Gross Profit | 47.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -13.1x | XXX | -15.2x | XXX | XXX | XXX |
| EV/FCF | -13.4x | XXX | -14.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPYC Therapeutics's last 12 month revenue growth is 67%
PYC Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $7.8M for the same period.
PYC Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PYC Therapeutics's rule of X is -259% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PYC Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 67% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -427% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -259% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $7.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PYC Therapeutics acquired XXX companies to date.
Last acquisition by PYC Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . PYC Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was PYC Therapeutics founded? | PYC Therapeutics was founded in 2001. |
| Where is PYC Therapeutics headquartered? | PYC Therapeutics is headquartered in Australia. |
| How many employees does PYC Therapeutics have? | As of today, PYC Therapeutics has 5 employees. |
| Is PYC Therapeutics publicy listed? | Yes, PYC Therapeutics is a public company listed on ASX. |
| What is the stock symbol of PYC Therapeutics? | PYC Therapeutics trades under PYC ticker. |
| When did PYC Therapeutics go public? | PYC Therapeutics went public in 2005. |
| Who are competitors of PYC Therapeutics? | Similar companies to PYC Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of PYC Therapeutics? | PYC Therapeutics's current market cap is $453M |
| What is the current revenue of PYC Therapeutics? | PYC Therapeutics's last 12 months revenue is $8.9M. |
| What is the current revenue growth of PYC Therapeutics? | PYC Therapeutics revenue growth (NTM/LTM) is 67%. |
| What is the current EV/Revenue multiple of PYC Therapeutics? | Current revenue multiple of PYC Therapeutics is 47.6x. |
| Is PYC Therapeutics profitable? | Yes, PYC Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PYC Therapeutics? | PYC Therapeutics's last 12 months EBITDA is -$37.9M. |
| What is PYC Therapeutics's EBITDA margin? | PYC Therapeutics's last 12 months EBITDA margin is -427%. |
| What is the current EV/EBITDA multiple of PYC Therapeutics? | Current EBITDA multiple of PYC Therapeutics is -11.1x. |
| What is the current FCF of PYC Therapeutics? | PYC Therapeutics's last 12 months FCF is -$31.5M. |
| What is PYC Therapeutics's FCF margin? | PYC Therapeutics's last 12 months FCF margin is -355%. |
| What is the current EV/FCF multiple of PYC Therapeutics? | Current FCF multiple of PYC Therapeutics is -13.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
